Hedgehog pathway inhibitors provide an FDA-approved treatment option with antitumor activity for advanced basal cell carcinoma, though they are associated with specific adverse effects.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Marcus Bernardus Nienhuis (2008) conducted a review in Locally advanced or metastatic basal cell carcinoma. Hedgehog pathway inhibitors was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: